SIMO vs PHIO vs MRVL vs SRPT

For growth investors, Marvell Technology, Inc.

(MRVL) is the stronger pick with 42. 1% revenue growth year-over-year, versus 10. 2% for Silicon Motion Technology Corporation (SIMO). Silicon Motion Technology Corporation (SIMO) offers the better valuation at 16. 6x trailing P/E (29. 9x forward), making it the more compelling value choice. Analysts rate Silicon Motion Technology Corporation (SIMO) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Silicon Motion Technology Corporation (SIMO) is the cheapest at 16.

6x versus Marvell Technology, Inc. at 52. 1x. On forward P/E, Sarepta Therapeutics, Inc. is actually cheaper at 6. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Silicon Motion Technology Corporation (SIMO) delivered a total return of +267.

4%, compared to -99. 6% for Phio Pharmaceuticals Corp. (PHIO). Over 10 years, the gap is even starker: MRVL returned +1581% versus PHIO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Phio Pharmaceuticals Corp.

(PHIO) is the lower-risk stock at 1. 59β versus Marvell Technology, Inc. 's 2. 21β — meaning MRVL is approximately 39% more volatile than PHIO relative to the S&P 500. On balance sheet safety, Marvell Technology, Inc. (MRVL) carries a lower debt/equity ratio of 31% versus 91% for Sarepta Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Marvell Technology, Inc.

(MRVL) is pulling ahead at 42. 1% versus 10. 2% for Silicon Motion Technology Corporation (SIMO). On earnings-per-share growth, the picture is similar: Marvell Technology, Inc. grew EPS 401. 0% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, SRPT leads at 33. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Marvell Technology, Inc.

(MRVL) is the more profitable company, earning 32. 6% net margin versus -32. 5% for Sarepta Therapeutics, Inc. — meaning it keeps 32. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRVL leads at 16. 1% versus -29. 9% for SRPT. At the gross margin level — before operating expenses — SRPT leads at 59. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sarepta Therapeutics, Inc.

(SRPT) trades at 6. 9x forward P/E versus 41. 7x for Marvell Technology, Inc. — 34. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SRPT: 18. 4% to $24. 63.

In this comparison, SIMO (3.

3% yield), MRVL (0. 1% yield) pay a dividend. PHIO, SRPT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Marvell Technology, Inc.

(MRVL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+1581% 10Y return). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MRVL: +1581%, SRPT: +18. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SIMO (Technology) and PHIO (Healthcare) and MRVL (Technology) and SRPT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SIMO is a small-cap deep-value stock; PHIO is a small-cap quality compounder stock; MRVL is a mid-cap high-growth stock; SRPT is a small-cap high-growth stock. SIMO pays a dividend while PHIO, MRVL, SRPT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.